Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-intensity immunosuppression for COVID-19 cytokine release syndrome
NL-OMON20650Recruiting
- Sponsor
- Zuyderland
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of methylprednisolone and tocilizumab in coronavirus pneumonia, sponsored by Zuyderland. Primary endpoint: Time to clinical improvement. Started Apr 2020; status: recruiting.
02
Drugs
methylprednisolonetocilizumab
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on NL-OMON20650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20650.